INCYTE INVESTOR EVENT AT ESMO 2026 - MORPHOSYS AG

Financial Performance:

• No specific revenue, earnings, cash flow, debt, or profit margin figures were disclosed in the transcript, as the company focuses on clinical development milestones rather than commercial sales at this stage.
• The portfolio targets approximately 250,000 new patients annually across key indications (Microsatellite Stable Colorectal Cancer, KRAS G12D Pancreatic Cancer, and CCNE1 Ovarian Cancer), representing a significant potential commercial opportunity once approved.
• Capital deployment is focused on advancing three core late-stage programs (890, 734, and 667) with significant resource allocation to Phase 3 trials.

Guidance and Future Outlook:

• Top-line Data Milestones: Top-line data for the Phase 3 DAWN-303 study (734 in Pancreatic Cancer) is expected in 2028; top-line data for the Phase 3 NexEra study (890 in Colorectal Cancer) is expected in 2029.
• Pivtrial Initiation: A Phase 3 study for 734 in KRAS G12D-mutated Colorectal Cancer is planned to initiate in the first half of 2027.
• Adjuvant Strategies: A proof-of-concept adjuvant study for 890 in ctDNA-positive colorectal cancer is currently enrolling, with an adjuvant Phase 3 study for 734 in Pancreatic Cancer scheduled to begin in 2027.
• Commercialization Goals: The company aims to transition from clinical development to commercialization of a "world-class solid tumor franchise" by leveraging first-in-class mechanisms and moving treatments to earlier lines of therapy (frontline and adjuvant).

Business Segments and Product Lines:

• Approved Product: Zeoprix (Zolifloxacin?) is approved for anal cancer (first PD-1 approved in combination with chemo for frontline anal cancer) and Merkel cell carcinoma; however, the current strategic focus is on solid tumor development beyond this asset.
• Program 890 (INC-A33890): A TGF-beta R2 by PD-1 bispecific antibody. Key data presented shows a 71% Overall Response Rate (ORR) and 100% Disease Control Rate (DCR) in first-line Microsatellite Stable (MSS) colorectal cancer (CRC) when combined with FOLFOX/Bevacizumab. Notable activity includes 83% ORR in patients with liver metastases.
• Program 734 (INCB161734): A selective KRAS G12D "on-and-off" inhibitor.
  • Pancreatic Ductal Adenocarcinoma (PDAC): Phase 1 data shows ORR of 69% (Gem/Abx) and 89% (mFOLFIRINOX), with 80-90% 6-month PFS, significantly outperforming historical benchmarks.
  • Colorectal Cancer: Phase 1 data in second/third-line settings combined with Cetuximab showed 36% ORR and a 100% DCR, compared to <5% ORR with standard of care.
• Program 667: A CDK2 inhibitor in pivotal trials for CCNE1-overexpressing ovarian cancer, with plans to continue progression.
• Partnerships & Collaborations: Announced collaborations to expand 734 with BMS (Nevilimstat/PRMT5 inhibitor), Synovium (SFV1521/PARP1 inhibitor), and Genmab (Pedocentamab/EGFR-LGR5 bispecific). Also collaborating on 890 with Next Generation (anti-CTLA-4) and exploring EGFR antibodies and ADCs.

Market and Competitive Landscape:

• TGF-beta vs. PD-1: 85% of colorectal cancers are MSS and currently resistant to standard checkpoint inhibitors (PD-1 alone). 890 targets the TGF-beta pathway which is hyperactivated in these tumors, particularly in liver metastases, addressing a major unmet need.
• KRAS G12D Competition: 734 is the only KRAS G12D "on-and-off" inhibitor in Phase 3. Management asserts its data is currently comparable to or leading the competitive landscape (specifically Selpercatinib/Alsetoribin/Sotorasib equivalents in other contexts, though the transcript specifically references Sotorasib/Seldoxanib as competitors in the Q&A).
• First-Mover Advantage: Management emphasizes the critical importance of being the first to market in PDAC and CRC to establish physician familiarity with toxicity management and dosing protocols, citing this as a potential barrier to entry for competitors.
• Market Dynamics: The landscape is becoming crowded with multiple bispecifics and combination strategies; management believes their "on-off" mechanism and specific targeting of liver metastases (via TGF-beta) provide a distinct biological differentiation.

Risks and Challenges:

• Safety Profiles: Potential for immune-related adverse events (irAEs) and GI toxicities (nausea, vomiting) are noted, though current data suggests they are manageable with dose intensity remaining high (67-69% vs historical ~75%).
• Myocarditis: Four cases of asymptomatic myocarditis observed in the 890 program (incidence <1%), deemed consistent with background rates of PD-1 inhibitors.
• Clinical Trial Risks: Dependence on Phase 3 success for both 890 (2029) and 734 (2028) for regulatory approval; uncertainty regarding the durability of responses and long-term overall survival (OS) signals.
• Combination Complexity: Managing the complexity of multiple combination regimens (chemo + targeted + bispecifics) and determining the optimal backbone for future trials (e.g., standard chemotherapy vs. targeted-only regimens).
• Competitive Pressure: The rapid advancement of other KRAS inhibitors and TGF-beta/PD-1 bispecifics could impact first-mover advantage if competitors demonstrate superior efficacy or safety.

Management Commentary and Tone:

• Confidence: Management expressed high conviction and confidence, stating that the presented data "substantially de-risks" the ongoing pivotal trials.
• Differentiation: Emphasized the unique "on-and-off" mechanism of 734 and the tissue-selective blockade of 890 as key differentiators from previous TGF-beta approaches which suffered from toxicity.
• Strategic Focus: Strong emphasis on "frontline" and "adjuvant" settings to maximize patient benefit and commercial value, moving away from late-line treatments.
• Internal Development: Highlighted pride in discovering and developing both 890 and 734 internally, reinforcing the company's drug discovery capabilities.

Analyst Questions and Answers:

• Overall Survival (OS) Necessity: For the DAWN-303 study, while OS is a primary endpoint, management indicated that a combination of PFS, ORR, and a positive trend in OS would likely suffice for approval, potentially allowing for accelerated pathways.
• On-Off vs. On Mechanism: Management explained that the "on-off" mechanism of 734 targets both GDP-bound (60-70% of pool) and GTP-bound states, theoretically providing more maximal inhibition and durable responses compared to "on-only" inhibitors which lose coverage during troughs.
• Partner Selection (PRMT5): The partnership with BMS for Nevilimstat was chosen primarily because the asset is already in pivotal trials, reducing risk compared to earlier-stage competitors.
• Chemotherapy Role: Management expects chemotherapy to remain the standard of care in first-line settings for the near future, with non-chemo targeted combinations potentially displacing it later, though likely not for several years.
• Bispecific Landscape (890): While acknowledging competition from other PD-1/TGF-beta bispecifics, management stressed the specific biology of TGF-beta in CRC and liver metastases as a strong rationale for 890's success.
• Toxicity Management: GI toxicities are proactive; patients are educated on managing side effects, and rates of discontinuation due to toxicity remain low.

Other Key Points:

• Adjuvant Strategy: A specific focus on ctDNA-positive patients in the adjuvant setting for 890, using ctDNA clearance as a proof-of-concept endpoint for disease-free survival.
• Combination Pipeline: 734 is expanding into combinations with EGFR-LGR5 bispecifics (Pedocentamab) and PARP1 inhibitors, while 890 is exploring combinations with anti-CTLA-4 and ADCs.
• Global Enrollment: The DAWN-303 and NexEra studies are enrolling globally at an accelerated pace, with DAWN-303 expected to complete accrual rapidly.
• Internal Innovation: Reiteration that both lead assets were discovered and developed entirely by the Insight team, specifically under the leadership of CSO Patrick Mace.